Liquid Profiling of Circulating Tumor DNA in Plasma of Melanoma Patients for Companion Diagnostics and Monitoring of BRAF Inhibitor Therapy

Clinical Chemistry
Verena HaselmannMichael Neumaier

Abstract

The current standard for determining eligibility of patients with metastatic melanoma for BRAF-targeted therapy is tissue-based testing of BRAF mutations. As patients are rarely rebiopsied, detection in blood might be advantageous by enabling a comprehensive assessment of tumor mutational status in real time and thereby representing a noninvasive biomarker for monitoring BRAF therapy. In all, 634 stage I to IV melanoma patients were enrolled at 2 centers, and 1406 plasma samples were prospectively collected. Patients were assigned to 3 separate study cohorts: study 1 for assessment of circulating tumor DNA (ctDNA) as part of companion diagnostics, study 2 for assessment of ctDNA for patients with low tumor burden and for follow-up, and study 3 for monitoring of resistance to BRAF inhibitor (BRAFi) or mitogen-activated protein kinase inhibitor therapy. Overall, a high degree of concordance between plasma and tissue testing results was observed at 90.9% (study 1) and 90.1% (study 2), respectively. Interestingly, discrepant results were in some cases associated with nonresponse to BRAFi (n = 3) or a secondary BRAF-mutant malignancy (n = 5). Importantly, ctDNA results correlated with the clinical course of disease in 95.7% and with...Continue Reading

References

Nov 1, 2005·Proceedings of the National Academy of Sciences of the United States of America·Frank DiehlBert Vogelstein
Jun 23, 2006·Nature Methods·Frank DiehlDevin Dressman
Aug 2, 2008·Nature Medicine·Frank DiehlLuis A Diaz
Dec 23, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·E A EisenhauerJ Verweij
Nov 18, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Charles M BalchVernon K Sondak
Oct 20, 2010·Archives of Dermatology·Vincenzo De GiorgiDaniela Massi
Jan 26, 2011·Clinica Chimica Acta; International Journal of Clinical Chemistry·Pamela PinzaniClaudio Orlando
May 17, 2011·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Alberto FusiUlrich Keilholz
Aug 25, 2011·Clinica Chimica Acta; International Journal of Clinical Chemistry·Michael FleischhackerStefan Holdenrieder
Mar 17, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Michaela J HigginsBen H Park
Jul 24, 2012·Cell·Eran HodisLynda Chin
Mar 15, 2013·The New England Journal of Medicine·Sarah-Jane DawsonNitzan Rosenfeld
Feb 21, 2014·Science Translational Medicine·Chetan BettegowdaLuis A Diaz
Sep 30, 2014·The New England Journal of Medicine·James LarkinAntoni Ribas
Nov 18, 2014·The New England Journal of Medicine·Caroline RobertDirk Schadendorf
Aug 28, 2015·Science Translational Medicine·Isaac Garcia-MurillasNicholas C Turner
Oct 9, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ademi Santiago-WalkerAnne-Marie Martin
Aug 26, 2017·Clinical Chemistry and Laboratory Medicine : CCLM·Verena HaselmannMichael Neumaier

❮ Previous
Next ❯

Citations

Aug 18, 2018·Annals of Clinical Biochemistry·Michael J Duffy
Oct 10, 2019·Pharmacogenomics·Guillaume HerbreteauMarc G Denis
Oct 31, 2019·Clinical Chemistry and Laboratory Medicine : CCLM·Nick NeuwingerKai Kappert
Sep 25, 2020·British Journal of Cancer·Laura KellerKlaus Pantel
Mar 13, 2019·Journal of Internal Medicine·G BarbanyE Tham
Feb 16, 2021·The Lancet Oncology·Andrea Forschner
Apr 4, 2021·Cancer Discovery·Catherine Alix-Panabières, Klaus Pantel

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Metabolic Reprogramming (Keystone)

Cancer metabolic reprogramming is important for the rapid growth and proliferation of cancer cells. Cancer cells have the ability to change their metabolic demands depending on their environment, regulated by the activation of oncogenes or loss of tumor suppressor genes. Here is the latest research on cancer metabolic reprogramming.

Cancer Metabolic Reprogramming

Cancer metabolic reprogramming is important for the rapid growth and proliferation of cancer cells. Cancer cells have the ability to change their metabolic demands depending on their environment, regulated by the activation of oncogenes or loss of tumor suppressor genes. Here is the latest research on cancer metabolic reprogramming.

© 2022 Meta ULC. All rights reserved